Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: up to 5-year results from the daily practice BioDay Registry

Junfen Zhang; Celeste M Boesjes; Laura Loman; Esmé Kamphuis; Margreet L E Romeijn; Lotte S Spekhorst; Inge Haeck; Lian F van der Gang; Coco C Dekkers; Lisa P van der Rijst; Albert J Oosting; Paula van Lumig; Anneke M T van Lynden-van Nes; Ron A Tupker; Annieke Nijssen; Annebeth Flinterman; Klaziena Politiek; Wouter R H Touwslager; Wianda A Christoffers; Shiarra M Stewart; Marijke Kamsteeg; Marlies de Graaf; Marjolein S de Bruin-Weller; Marie-Louise A Schuttelaar

doi:10.1016/j.jaad.2024.04.026

Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: up to 5-year results from the daily practice BioDay Registry

J Am Acad Dermatol. 2024 Apr 21:S0190-9622(24)00641-8. doi: 10.1016/j.jaad.2024.04.026. Online ahead of print.

Authors

Junfen Zhang¹, Celeste M Boesjes², Laura Loman¹, Esmé Kamphuis¹, Margreet L E Romeijn¹, Lotte S Spekhorst², Inge Haeck³, Lian F van der Gang², Coco C Dekkers², Lisa P van der Rijst², Albert J Oosting⁴, Paula van Lumig⁵, Anneke M T van Lynden-van Nes⁶, Ron A Tupker⁷, Annieke Nijssen⁸, Annebeth Flinterman⁹, Klaziena Politiek¹⁰, Wouter R H Touwslager¹¹, Wianda A Christoffers¹², Shiarra M Stewart¹³, Marijke Kamsteeg¹⁴, Marlies de Graaf², Marjolein S de Bruin-Weller², Marie-Louise A Schuttelaar¹⁵

Affiliations

¹ Department of Dermatology, University Medical Center Groningen, Groningen, The Netherlands.
² National Expertise Center for Atopic Dermatitis, Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, The Netherlands.
³ Department of Dermatology, Reinier de Graaf Hospital, Delft, The Netherlands.
⁴ Department of Dermatology, Spaarne Gasthuis, Hoofddorp, The Netherlands.
⁵ Department of Dermatology, University Medical Center Maastricht, Maastricht, The Netherlands.
⁶ Department of Dermatology, Meander Medical Center, Amersfoort, The Netherlands.
⁷ Department of Dermatology, St Antonius Hospital, Nieuwegein, The Netherlands.
⁸ Department of Dermatology, Haga Hospital, Den Haag, The Netherlands.
⁹ Department of Dermatology, Diakonessenhuis, Utrecht, The Netherlands.
¹⁰ Department of Dermatology, Medical Center Leeuwarden, Leeuwarden, The Netherlands.
¹¹ Department of Dermatology, Catharina Hospital, Eindhoven, The Netherlands.
¹² Department of Dermatology, Isala Hospital, Zwolle, The Netherlands.
¹³ Department of Dermatology, IJsselland Hospital, Capelle aan den IJssel, The Netherlands.
¹⁴ Department of Dermatology, Radboud University Medical Center, Nijmegen, The Netherlands.
¹⁵ Department of Dermatology, University Medical Center Groningen, Groningen, The Netherlands. Electronic address: m.l.a.schuttelaar@umcg.nl.

PMID: 38653344
DOI: 10.1016/j.jaad.2024.04.026

Abstract

Background: Long-term daily practice data on patient-reported benefits of dupilumab for atopic dermatitis (AD) remains limited.

Objective: To evaluate patient-reported outcome measures (PROMs) and the safety of dupilumab in patients with moderate-to-severe AD over a follow-up period of up to 5 years.

Methods: Data were extracted from the prospective, multicenter BioDay registry (October 2017 - 2022) of patients with moderate-to-severe AD treated with dupilumab in daily practice.

Results: In total 1223 patients, 1108 adults and 115 pediatric patients, were included. After ≥1 year of treatment, mean Patient-Oriented Eczema Measure (POEM), Dermatology Life Quality Index (DLQI), Numeric rating scale (NRS)-pruritus ranged between 7.8-8.7, 3.5-4.2, and 2.9-3.1 in adults, respectively, whilst these PROMs ranged between 8.9-10.9, 4.4-6.4, and 3.0-3.7 in pediatric patients, respectively. At follow-up, overall work impairment decreased from 40.1% to 13.3-16.3% in adults. Furthermore, class I obesity and itch-dominant patients generally had less favorable treatment response. Of all patients, 66.8% reported ≥1 adverse event, with conjunctivitis being the most common(33.7%).

Limitations: The overall percentage of missing values for selected PROMs was 26% in adults and 46% in pediatric patients.

Conclusion: In addition to favorable safety, dupilumab has demonstrated sustained effectiveness across various PROMs, underscoring the treatment benefits from patients' perspectives.

Keywords: atopic dermatitis; atopic eczema; daily practice; dupilumab; effectiveness; patient-reported outcomes; safety.